A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

A year ago Eli Lilly and Boehringer Ingelheim produced results which showed their oral SGLT2 inhibitor drug Jardiance (empagliflozin ... semaglutide 0.5 mg and 1.0 mg significantly reduced ...

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of ...

and Boehringer Ingelheim and Eli Lilly’s Type 2 diabetes drug Jardiance, the last of which previously took the seventh spot on this list in October. All together, drugmakers threw $274.4 million ...

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...

JSW MG Motor India has unveiled two new cars at the Bharat Mobility Global Expo 2025. Introducing the MG Cyberster, India’s first all-electric roadster, and the MG M9, the country’s first ...

The M9 positions MG in the premium electric MPV segment and will be offered exclusively through the brand's 'Select' dealerships MG to retail the premium M9 MPV via its new ‘Select’ dealerships.

with the U.S. Food and Drug Administration (FDA). However, BCVA data across all study timepoints demonstrated an improvement in vision, increasing over time, and the presence of biologic activity.

Expected to be priced from Rs 46 lakh (ex-showroom). The MG Majestor has been revealed at the Bharat Mobility Global Expo 2025 as the carmaker's flagship SUV in India. The MG Majestor gets ...

Under the finalized guidance for the second negotiation cycle, drug manufacturers have until February 28, 2025, to decide on their participation. CMS will evaluate factors such as the drug's ...

The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute myocardial infarction (AMI) and unstable angina, an aging global population, ...

Jan. 13, 2025 — A new study found no changes in opioid outcomes among the general population with the states' passage of medical and recreational marijuana laws. However, the findings also show ...